Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 272-032-5 | CAS number: 68649-48-9
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Endpoint summary
Administrative data
Key value for chemical safety assessment
Genetic toxicity in vitro
Link to relevant study records
- Endpoint:
- in vitro cytogenicity / chromosome aberration study in mammalian cells
- Type of information:
- read-across from supporting substance (structural analogue or surrogate)
- Adequacy of study:
- key study
- Justification for type of information:
- REPORTING FORMAT FOR THE ANALOGUE APPROACH
see read-across justifocation in section Chapter 13 - Reason / purpose for cross-reference:
- read-across source
- Key result
- Species / strain:
- lymphocytes: Human
- Metabolic activation:
- with and without
- Genotoxicity:
- negative
- Cytotoxicity / choice of top concentrations:
- not determined
- Vehicle controls validity:
- valid
- Untreated negative controls validity:
- not examined
- Positive controls validity:
- valid
- Remarks on result:
- other: all strains/cell types tested
- Remarks:
- Migrated from field 'Test system'.
- Conclusions:
- Interpretation of results (migrated information):
negative
Under the conditions of the test, the test material was determined to be non-clastogenic to human lymphocytes. There was no statistically significant increase in the frequency of cell aberrations in the absence or presence of metabolic activation. - Executive summary:
In a GLP compliant chromosome aberration study performed according to the standardised guidelines; OECD 473, EU Method B.10 and UK department of Health Committee on Mutagenicity Guidelines for the Mutagenicity Testing of Chemicals, the test material was determined to be non-clastogenic. Under the conditions of the test the human lymphocyte did not produce a statistically significant increase in the frequency of cell aberrations in the absence or presence of metabolic activation. Therefore the test material is considered to be non-mutagenic.
- Endpoint:
- in vitro gene mutation study in mammalian cells
- Remarks:
- Type of genotoxicity: Mouse Lymphoma Assay
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Study period:
- 2nd January 2014 to 10th April 2014
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- guideline study
- Qualifier:
- according to guideline
- Guideline:
- OECD Guideline 476 (In Vitro Mammalian Cell Gene Mutation Test)
- Deviations:
- no
- Qualifier:
- according to guideline
- Guideline:
- EU Method B.17 (Mutagenicity - In Vitro Mammalian Cell Gene Mutation Test)
- Deviations:
- no
- GLP compliance:
- yes
- Type of assay:
- mammalian cell gene mutation assay
- Target gene:
- Thymidine kinase, TK +/-, locus in L5178Y mouse lymphoma cells. Mutant form is TK-/-
- Species / strain / cell type:
- mouse lymphoma L5178Y cells
- Details on mammalian cell type (if applicable):
- - Type and identity of media: The following culture media were used; minimal medium A, minimal medium B, complete medium (5 %), complete medium (10 %), complete medium A (20 %) and complete medium B (20 %). The compositions of media can be seen in Table 1 in the field “any other information on materials and methods incl. tables”.
- Properly maintained: Yes, Permanent stocks of the L5178Y TK+/- cells are stored in liquid nitrogen, and subcultures are prepared from the frozen stocks for experimental use.
- Periodically checked for Mycoplasma contamination: Yes.
- Periodically "cleansed" against high spontaneous background: Yes. - Additional strain / cell type characteristics:
- not applicable
- Metabolic activation:
- with and without
- Metabolic activation system:
- S9 mix
- Test concentrations with justification for top dose:
- Main Assay I (with and without metabolic activation): 6.25, 12.5, 25.0, 50.0 and 100 µg/mL
Main Assay II (without metabolic activation): 6.25, 12.5, 25.0, 50.0 and 100 µg/mL
Main Assay II (with metabolic activation): 19.8, 29.6, 44.4, 66.7 and 100 µg/mL - Vehicle / solvent:
- - Vehicle(s)/solvent(s) used: DMSO
- Justification for choice of solvent/vehicle: This solvent was selected since it is compatible with the survival of the cells and the S9 metabolic activity. - Untreated negative controls:
- no
- Negative solvent / vehicle controls:
- yes
- Remarks:
- DMSO
- True negative controls:
- no
- Positive controls:
- yes
- Positive control substance:
- benzo(a)pyrene
- methylmethanesulfonate
- Details on test system and experimental conditions:
- METHOD OF APPLICATION: in medium. A cell suspension (1 x 10^6 cells/mL) in complete medium was prepared. A common pool was used for each experiment to prepare the test cultures in appropriately labelled conical screw-cap tissue culture tubes. The treatment media were prepared as follows, with a total volume of 20 mL:
-3 hour exposure time, without S9 metabolism: 10.0 mL of cell suspension (1 x 10^6 cells/mL in complete medium 5 %), 9.8 mL complete medium (5 %) and 0.2 mL of the control or appropriate test solution.
-24 hour exposure time, without S9 metabolism: 3.0 mL of cell suspension (1 x 10^6 cells/mL in complete medium 10 %), 16.8 mL complete medium (10 %), and 0.2 mL of the control or appropriate test solution.
-3 hour exposure time, with S9 metabolic activation: 10.0 mL of cell suspension (1 x 10^6 cells/mL in complete medium 5 %), 9.8 mL S9 mix, and 0.2 mL of the control or appropriate test solution.
The cultures were incubated with the test solution at 37 °C. At the end of the exposure period, the treatment medium was removed and the cultures centrifuged and washed twice with Phosphate Buffered Saline (PBS).
After washing cells were resuspended in fresh complete medium (10 %) and cell densities were determined. The number of cells was adjusted to give 2 x 10^5 cells/mL.
The cultures were incubated at 37 °C in a 5 % CO2 atmosphere (100 % nominal relative humidity) to allow for expression of the mutant phenotype.
Determination of Survival
Following adjustment of the cell densities, samples of the cultures were diluted to 8 cell/mL using complete medium A (20 %). A 0.2 mL aliquot of each diluted culture was placed into each well of two 96-well plates. The plates were incubated at 37 °C in a 5 % CO2 atmosphere (100 % nominal relative humidity) for 6 - 9 days. After incubation, wells containing viable clones were identified by the eye using background illumination and then counted.
Expression Period
During the expression period (two days after treatment) the cell populations were subcultured in order to maintain them in exponential growth. At the end of this period the cell densities of each culture were determined and adjusted to give 2 x 10^5 cells/mL.
Plating for 5-Trifluorothymidine Resistance
After dilution, the cell suspensions in complete medium B (20 %) were supplemented with trifluorothymidine (final concentration 3.0 µg/mL) and an estimated 2 x 10^3 cells were plated in each well of four 96-well plates.
Plates were incubated at 37 °C in a 5 % CO2 atmosphere (100 % nominal relative humidity) for 12 - 13 days and wells containing clones were identified as described above and counted. In addition, the number of wells containing large colonies and the number containing small colonies were scored.
Plating for Viability
After dilution, in complete medium A (20 %), an estimated 1.6 cells/well were plated in each well of two 96-well plates. These plates were incubated at 37 °C in a 5 % CO2 atmosphere (100 % nominal relative humidity) for 12 - 13 days and wells containing clones were identified as above and counted.
DURATION
- Exposure duration:
> Main Assay I:
Assay 1: 3 hours, with and without metabolic activation.
>Main Assay II:
Assay 2: 24 hours, without metabolic activation.
Assay 3: 3 hours, with metabolic activation.
- Expression time (cells in growth medium): 6 to 9 days.
NUMBER OF REPLICATIONS: Duplicate cultures were prepared for each test concentration, with the exception of the positive controls which were prepared in a single culture.
DETERMINATION OF CYTOTOXICITY
- Method: Relative survival value, cell count factors, raw plate counts.
PRELIMINARY TEST
A preliminary cytotoxicity test was performed in order to select appropriate dose levels for the mutation assays. In this test a wide range of dose levels of the test item were used and the survival of the cells was subsequently determined.
Treatments wee performed in the absence and presence of S9 metabolic activation for 3 hours and for 24 hours only in the absence of S9 metabolic aqctivation. A single culture was used at each test point. After washing in Phosphate Buffered Saline (PBS) , cells were resuspended in 20 mL of complete medium (10%). Cell concentrations were adjusted to 8 cells/mL using complete medium (20%) and, for each dose elvel, 0.2 mL was plated into 96 microtitre wells. The plates were incubated at 37 degs. C in a 5% CO2 atmosphere (100% relative humidity) for 7 days. Wells containing viable clones were identified by eye using background illumination and then counted. - Evaluation criteria:
- For a test item to be considered mutagenic in this assay, it is required that:
1) The induced mutant frequency (IMF) is higher than the global evaluation factor (GEF) suggested for the microwell method (126 x 10^-6) at one or more doses.
2) There is a significant dose-relationship as indicated by the linear trend analysis.
Results which only partially satisfy the above criteria will be dealt with on a case-by-case basis. Similarly, positive responses seen only at high levels of cytotoxicity will require careful interpretation when assessing their biological significance. Any increase in mutant frequency should lie outside the historical control range to have biological relevance. - Statistics:
- Statistical analysis was performed according to UKEMS guidelines (Robinson W.D., 1990). The following were calculated:
- Test for consistency between plates
- Heterogeneity factors for replicate cultures
- Test for overall consistency
- Updated heterogeneity factors
- Comparison of each treatment with the control
- Test for linear trend - Key result
- Species / strain:
- mouse lymphoma L5178Y cells
- Metabolic activation:
- with and without
- Genotoxicity:
- negative
- Cytotoxicity / choice of top concentrations:
- cytotoxicity
- Remarks:
- In Main Assay I; with 3 hour exposure with S9 at 50.0 and 100 µg/mL.
- Vehicle controls validity:
- valid
- Untreated negative controls validity:
- not examined
- Positive controls validity:
- valid
- Additional information on results:
- TEST-SPECIFIC CONFOUNDING FACTORS
- Effects of osmolality and pH: Addition of the test solution did not have any obvious effect on the osmolality or pH of the treatment medium.
- Precipitation:
> In Main Assay I, in the absence of S9 metabollic activation, higher than usual heterogenicity was observed in plate counts for mutation between Culture B replicate plate at 12.5 µg/mL and between replicate cultures at 50 µg/mL. Because of the inclusion of this last dose in analysis, the overall heterogeneity between cultures was higher than usual. Since this was probably due to the presence of test item precipitation in the treatment mixture, it was not considered to have affected the validity of the study.
ADDITIONAL INFORMATION ON CYTOTOXICITY: Both in the absence and presence of S9 metabolic activation, the test item was assayed at a maximum dose level of 100 µg/mL and at a wide range of lower dose levels: 50.0, 25.0, 12.5, 6.25, 3.13, 1.56, 0.781 and 0.391 µg/mL. Upon addition of the test items to the cultures, in the absence of S9 metabolism, a slight cloudy appearance of the treatment medium was noted at the two highest concentrations. At the end of the 3 hour treat period, a dose-related cloudy appearance was observed starting from 12.5 µg/mL, both in the absence and presence of S9 metabolic activation; while by the end of the 24 hour treat period, no opacity was noted.
In the absence of S9 metabolic activation, using both the 3 and 24 hour treatment times, no toxicity was observed at any concentration tested. Following treatment in the presence of S9 metabolic activation, using the short treatment time (3 hours), slight toxicity was seen at the two highest concentrations (53 and 63% RS), while no relevant toxicity was observed over the remaining dose levels tested. - Remarks on result:
- other: all strains/cell types tested
- Remarks:
- Migrated from field 'Test system'.
- Conclusions:
- Interpretation of results (migrated information):
negative with and without metabolic activation
Under the conditions of the study, the test material did not induce mutation at the TK locus of L5178Y mouse lymphoma cells in vitro in the absence or presence of S9 metabolic activation. - Executive summary:
In a GLP compliant study performed to standardised guidelines OECD 476 and EU Method B.17, the mutagenic potential of the test material was evaluated in a mouse lymphoma assay. Mouse lymphoma L5178Y cells were exposed to the test material in two experiments at concentrations ranging from 6.25 to 100 µg/plate, both in the presence and absence of metabolic activation. Main Assay I was performed with an exposure time of 3 hours with and without metabolic activation. Main Assay II was performed for 3 hour with metabolic activation and for 24 hours without.
No mutant frequency above those seen in the concurrent solvent control or historical background ranges were observed following treatment with the test material, in the absence or presence of S9 metabolism.
It was concluded that under the conditions of the study, the test material did not induce mutation at the TK locus of L5178Y mouse lymphoma cells in vitro in the absence or presence of S9 metabolic activation.
- Endpoint:
- in vitro gene mutation study in bacteria
- Remarks:
- Type of genotoxicity: Ames-Test
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Study period:
- 23 May 2008 to 13 June 2008
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- guideline study with acceptable restrictions
- Qualifier:
- according to guideline
- Guideline:
- OECD Guideline 471 (Bacterial Reverse Mutation Assay)
- Deviations:
- no
- Qualifier:
- according to guideline
- Guideline:
- EU Method B.13/14 (Mutagenicity - Reverse Mutation Test Using Bacteria)
- Deviations:
- no
- Qualifier:
- according to guideline
- Guideline:
- other: ICH S2A Genotoxicity: Specific Aspects of Regulatory Tests, Step 5.
- Deviations:
- no
- GLP compliance:
- yes
- Type of assay:
- bacterial reverse mutation assay
- Target gene:
- Histidine and tryptophan operons in S. typhimurium and E. coli, respectively.
- Species / strain / cell type:
- S. typhimurium TA 1535, TA 1537, TA 98, TA 100 and E. coli WP2
- Details on mammalian cell type (if applicable):
- Type and identity of media:
- Nutrient Broth: Oxoid Nutrient Broth No. 2 was prepared at a concentration of 2.5 % in distilled water and autoclaved prior to use. This was used for the preparation of liquid cultures of the tester strains.
- Nutrient Agar: Oxoid Nutrient Broth No. 2 (25 g) and Difco Bacto-agar (15 g) were added to distilled water (1 litre) and autoclaved. The solutions were then poured into 9 cm plastic Petri dishes and allowed to solidify and dry before use. These plates were used for the non-selective growth of the tester strains.
- Minimal Agar: Minimal medium agar was prepared as 1.5 % Difco Bacto-agar in Vogel-Bonner Medium E, with 2 % Glucose, and poured into 9 cm plastic Petri dishes.
- Top Agar: "Top Agar" (overlay agar) was prepared as 0.6 % Difco Bacto-agar + 0.5 % NaCl in distilled water. Prior to use 10 mL of a sterile solution of 0.5 mM Biotin + 0.5 mM Histidine (or 0.5 mM tryptophan) was added to the top agar (100 mL).
- Properly maintained: Yes, permanent stocks of these strains are kept at -80 °C. Overnight subcultures of these stocks were prepared for each day's work. Bacteria were taken from vials of frozen cultures, which had been checked for the presence of the appropriate genetic markers, as follows:
> Histidine requirement: No Growth on Minimal plates + Biotin and Growth on Minimal plates + Biotin + Histidine.
> Tryptophan requirement: No Growth on Minimal agar plates and Growth on Minimal plates + Tryptophan.
> uvrA, uvrB: Sensitivity to UV irradiation.
> rfa: Sensitivity to Crystal Violet.
> pKM101: Resistance to Ampicillin. - Additional strain / cell type characteristics:
- other: uvrA, uvrB, rfa and pKM101.
- Metabolic activation:
- with and without
- Metabolic activation system:
- S9 fraction
- Test concentrations with justification for top dose:
- Main Assay I: 62.5, 125, 250, 500 and 1000 µg/plate
Main Assay II: 31.3, 62.5, 125, 250 and 500 µg/plate
Preliminary toxicity test: 0.0, 10.0, 31.6, 100, 316 and 1000 µg/plate - Vehicle / solvent:
- - Vehicle(s)/solvent(s) used: DMSO
- Justification for choice of solvent/vehicle: This solvent was selected since it is compatible with the survival of the bacteria and the S9 metabolic activity. - Untreated negative controls:
- no
- Negative solvent / vehicle controls:
- yes
- Remarks:
- DMSO
- True negative controls:
- no
- Positive controls:
- yes
- Positive control substance:
- 9-aminoacridine
- 2-nitrofluorene
- sodium azide
- methylmethanesulfonate
- other: 2-aminoanthracene
- Details on test system and experimental conditions:
- MAIN ASSAY I:
METHOD OF APPLICATION: in agar (plate incorporation). The components of the assay (0.1 mL of the tester strain bacteria, 0.1 mL of the test or control solution and 0.5 mL of the S9 mix or phosphate buffer (pH 7.4, 0.1 M)) were added to 2 mL of molten overlay agar (held at 45 °C) and vortexed. The mixture was then poured onto the surface of a minimal medium agar plate, and allowed to solidify prior to incubation.
MAIN ASSAY II:
METHOD OF APPLICATION: pre-incubation method. The following components were added in turn to an empty test-tube as follows: 0.1 mL of bacterial suspension, 0.05 mL of the appropriate test or control solution and 0.5 mL of S9 mix or phosphate buffer (pH 7.4, 0.1 M) as necessary. The incubate was vortexed and placed at 37 °C for 30 minutes. Two mL of overlay agar was then added and the mixture vortexed again and poured onto the surface of a minimal medium agar plate and allowed to solidify.
DURATION
- Preincubation period: 30 minutes for Main Assay II.
- Exposure duration: 72 hours, incubated at 37 °C.
NUMBER OF REPLICATIONS: Three.
SCORING: counting the number of revertant colonies on each plate.
DETERMINATION OF CYTOTOXICITY
- Method: Toxicity was assessed on the basis of a decline in the number of spontaneous revertants, a thinning of the background lawn or a microcolony formation.
OTHER EXAMINATIONS:
- Sterility check: Performed on the S9 mix, test solutions and bacterial cultures. Each substance was plated on nutrient agar plates to establish the number of bacteria in the cultures.
PRELIMINARY TOXICITY TEST:
- A preliminary toxicity test was performed in the presence and absence of metabolic activation using the plate incorporation method, a DMSO (100 µL) vehicle control was run concurrently. A single plate was used at each test point and positive controls were not included. Toxicity was assessed on the basis of a decline in the number of spontaneous revertants, a thinning of the background lawn or a microcolony formation. The results were used to determine the concentration levels for the definitive test.
- Precipitation: Precipitation was observed at the end of the incubation period at the two highest dose levels, 316 and 1000 µg/plate. This was, however, not considered to have interfered with the scoring of the revertant colonies.
- Toxicity: No toxicity was observed at any of the dose levels with any of the tester strains, in the absence or presence of metabolic activation. - Evaluation criteria:
- For the test material to be considered mutagenic, two-fold (or more) increases in mean revertant numbers must be observed at two consecutive dose levels or at the highest practicable dose level only. In addition, there must be evidence of a dose-response relationship showing increasing numbers of mutant colonies with increasing dose levels.
- Statistics:
- The mean and standard deviation for results from Main Assays I and II were calculated.
- Key result
- Species / strain:
- S. typhimurium TA 1535, TA 1537, TA 98, TA 100 and E. coli WP2
- Metabolic activation:
- with and without
- Genotoxicity:
- negative
- Cytotoxicity / choice of top concentrations:
- no cytotoxicity
- Vehicle controls validity:
- valid
- Untreated negative controls validity:
- not examined
- Positive controls validity:
- valid
- Additional information on results:
- TEST-SPECIFIC CONFOUNDING FACTORS
- Precipitation: Precipitation was observed at the end of the incubation period, in both Main Assays I and II. This was not considered to have interfered with the scoring of the revertant colonies.
> Main Assay I: precipitation at 1000 and 500 µg/plate.
> Main Assay II: precipitation at 500, 250 and 125 µg/plate.
- Other confounding effects: No plates were lost through contamination or cracking.
COMPARISON WITH HISTORICAL CONTROL DATA: Results show that mean plate counts for untreated and positive control plates fell within the normal historical range. The estimated numbers of viable bacteria/plate (titre) fell in the range of 100 - 500 millions for each strain.
ADDITIONAL INFORMATION ON CYTOTOXICITY:
- Toxicity: No toxicity was observed at any of the dose levels with any of the tester strains, in the absence or presence of metabolic activation for both Main Assays I and II.
STERILITY CONTROL
The sterility of the S9 mix and the test solutions were confirmed by the absence of colonies on additional agar plates spread separately with these solutions. - Remarks on result:
- other: all strains/cell types tested
- Remarks:
- Migrated from field 'Test system'. Remarks: Main Assay I
- Conclusions:
- Interpretation of results (migrated information):
negative with and without metabolic activation
The test material did not induce a two-fold increase in the number of revertant colonies, at any dose level up to the maximum concentration of 1000 µg/plate, in any tester strain, in the absence or presence of metabolic activation. It was therefore concluded that the test material is not mutagenic to S. typhimurium or E. coli under the conditions of the test. - Executive summary:
In a GLP compliant study performed to standardised guidelines OECD 471 and EU Method B.13/14, the mutagenic potential of the test material was assayed in an Ames Test. S. typhimurium TA 1535, TA 1537, TA 100, TA 98 and E. coli WP2uvrA were exposed to the test material in two experiments at concentrations ranging from 62.5 to 1000 µg/plate using the plate incorporation method and 31.3 to 500 µg/plate using the pre-incubation method. Both tests were performed with and without metabolic activation.
The test material did not induce an increase in the number of revertant colonies, at any dose level up to the maximum concentration of 1000 µg/plate, in any tester strain, in the absence or presence of metabolic activation. No toxicity was observed at any of the dose levels with any of the tester strains, in the absence or presence of metabolic activation for both Main Assays I and II. Precipitation was observed at the end of the incubation period, in Main Assay I ≥ 500 µg/plate and in Main Assay II ≥ 125 µg/plate. This was not considered to have interfered with the scoring of the revertant colonies. It was therefore concluded that under the conditions of the test, the test material is not mutagenic to S. typhimurium or E. coli.
Referenceopen allclose all
Experiment 1:
-The test material did not induce a statistically significant increase in the frequency of cells with aberrations either in the absence or presence of metabolic activation.
- The maximum dose level with scoreable metaphases present was 1250µg/ml in the presence and absence of metabolic activation. - The mitotic data confirms the qualitative assessment that the dose-related inhibition of mitotic index was observed and that 33% mitotic inhibition was achieved at 1250 µg/ml in the absence of S9 and 35% in the presence.
- Complete inhibition was observed at 1875 and 2500µg/mlin both exposure groups.
Experiment 2:
-The test material did not induce a statistically significant increase in the frequency of cells with aberrations either in the absence or presence of metabolic activation.
- Qualitative assessment of the slides determined that the maximum dose level with scorable metaphases was 1250µg/ml with S9 mix and 468.75µg/ml without S9 mix in experiment 2.
- The mitotic index data confirms the qualitative observations that a dose-related inhibition of mitotic index was observed and that 67% mitotic inhibition as achieved at 468.75 µg/ml in the absence of S9. In the presence of S9 50% mitotic inhibition was achieved at 1250 µg/ml.
Table 1. Results of Chromosome Aberrations
Experiment No. | With or Without S9 mix | Treatment Group | Dose Level (µg/ml) | Total No. of Aberrations | Frequency of Aberrant Cells (%) | ||
(+ Gaps) | (- Gaps) | (+ Gaps) | (- Gaps) | ||||
1 | Without | Vehicle Control | 2 | 1 | 1 | 1 | |
Test Material | 312.5 | 1 | 1 | 1 | 1 | ||
625 | 3 | 2 | 3 | 2 | |||
1250 | 2 | 1 | 2 | 1 | |||
1875 | TOXIC | ||||||
Positive Control MMC | 0.4 | 39 | 29 | 28 | 22*** | ||
1 | With | Vehicle Control | 7 | 5 | 3 | 1 | |
Test Material | 312.5 | 2 | 2 | 2 | 2 | ||
625 | 1 | 0 | 1 | 0 | |||
1250 | 5 | 3 | 5 | 3 | |||
1875 | TOXIC | ||||||
Positive Control CP | 10 | 89 | 50 | 65 | 39*** | ||
2 | Without | Vehicle Control | 3 | 3 | 3 | 3 | |
Test Material | 156.25 | 1 | 0 | 1 | 0 | ||
312.5 | 1 | 0 | 1 | 0 | |||
468.75 | 1 | 1 | 1 | 1 | |||
625 | TOXIC | ||||||
Positive Control MMC | 0.2 | 72 | 53 | 50 | 39*** | ||
2 | With | Vehicle Control | 2 | 1 | 2 | 1 | |
Test Material | 312.5 | 1 | 0 | 1 | 0 | ||
625 | 2 | 2 | 2 | 2 | |||
1250 | 8 | 3 | 8 | 3 | |||
Positive Control CP | 0.2 | 96 | 73 | 52 | 42*** |
MMC = Mitomycin C
CP = Cyclophosphamide
*** = P < 0.001
Table 2: Summary of Main Assay I
Dose Level (µg/mL) |
RS (%) |
RTG (%) |
MFØ |
P |
IMFØ |
Proportion Small Colony Mutants |
Precipitation |
3 Hours Without S9 |
|||||||
0 |
100 |
100 |
79.5 |
- |
- |
0.43 |
- |
6.25 |
125 |
141 |
50.0 |
NS |
- |
- |
- |
12.5 |
117 |
115 |
57.9 |
NS |
- |
- |
- |
25.0 |
127 |
130 |
71.4 |
NS |
- |
- |
+ |
50.0 |
129 |
133 |
77.0 |
NS |
- |
- |
+ |
100 |
129 |
119 |
89.0 |
NS |
9.56 |
- |
+ |
MMS (10.0) |
129 |
93 |
326.7 |
- |
247.3** |
0.49 |
- |
Linear Trend |
|
* |
|
||||
3 Hours With S9 |
|||||||
0 |
100 |
100 |
93.3 |
- |
- |
0.27 |
- |
6.25 |
88 |
98 |
83.5 |
NS |
- |
- |
- |
12.5 |
112 |
102 |
95.4 |
NS |
2.07 |
- |
- |
25.0 |
143 |
104 |
55.0 |
NS |
- |
- |
+ |
50.0 |
64 |
59 |
94.5 |
NS |
1.13 |
- |
+ |
100 |
71 |
62 |
67.8 |
NS |
- |
- |
+ |
B(a)P (2.00) |
42 |
18 |
1141.9 |
- |
1048.5** |
0.54 |
- |
Linear Trend |
|
NS |
|
Table 3: Summary of Main Assay II
Dose Level (µg/mL) |
RS (%) |
RTG (%) |
MFØ |
P |
IMFØ |
Proportion Small Colony Mutants |
Precipitation |
24 Hours Without S9 |
|||||||
0 |
100 |
100 |
60.3 |
- |
- |
0.34 |
- |
6.25 |
86 |
98 |
61.1 |
NS |
0.82 |
- |
- |
12.5 |
80 |
114 |
43.6 |
NS |
- |
- |
- |
25.0 |
97 |
96 |
59.2 |
NS |
- |
- |
- |
50.0 |
86 |
103 |
61.3 |
NS |
0.98 |
- |
+ |
100 |
90 |
97 |
66.3 |
NS |
6.01 |
- |
+ |
MMS (5.0) |
68 |
78 |
299.3 |
- |
239** |
0.34 |
- |
Linear Trend |
|
NS |
|
||||
3 Hours With S9 |
|||||||
0 |
100 |
100 |
67.6 |
- |
- |
0.30 |
- |
19.8 |
85 |
94 |
89.3 |
NS |
21.71 |
- |
- |
29.6 |
95 |
110 |
64.9 |
NS |
- |
- |
- |
44.4 |
99 |
112 |
70.5 |
NS |
2.89 |
- |
+ |
66.7 |
85 |
84 |
104.9 |
NS |
37.26 |
- |
+ |
100 |
91 |
103 |
92.1 |
NS |
24.53 |
- |
+ |
B(a)P (2.00) |
34 |
29 |
613.6 |
- |
546** |
0.38 |
- |
Linear Trend |
|
* |
|
Ø = per 10^6 viable cells
NS = Not statistically significant
* = Statistically significant at p < 5%
** = Induced mutant frequency (IMF) > global evaluation factor (GEF = 126 x 10^-6)
+ = Opacity of treatment medium
RS = Relative survival
RTG = Relative total growth
MF = Mutation frequency
IMF = Induced mutant frequency
MMS = methylmethanesulphonate
B(a)P = benzo(a)pyrene
Table 4: Historical Data, Mutation Frequency per Million Surviving Cells
|
Without S9, 3 hours |
With S9, 3 hours |
Without S9, 24 hours |
|||
Negative Control |
Positive Control |
Negative Control |
Positive Control |
Negative Control |
Positive Control |
|
Mean |
88.0 |
446 |
90.8 |
694 |
85.1 |
546 |
SD |
28.6 |
148 |
30.2 |
267 |
30.5 |
203 |
Upper Confidence Limit (P<1%) |
162 |
NC |
169 |
NC |
164 |
NC |
Min |
51 |
209 |
44.9 |
187 |
50.4 |
221 |
Max |
234 |
1103 |
234 |
1393 |
217 |
1950 |
n |
90 |
119 |
196 |
196 |
85 |
85 |
NC = not calculated; n = number of experiments.
Table 1: Preliminary Toxicity Test, Number of Revertant Colonies per Plate
Dose Level (µg/plate) |
Tester Strains Without Metabolic Activation |
Tester Strains With Metabolic Activation |
||||||||
TA 1535 |
TA 1537 |
TA 98 |
TA 100 |
WP2 uvrA |
TA 1535 |
TA 1537 |
TA 98 |
TA 100 |
WP2 uvrA |
|
Untreated |
19 |
17 |
27 |
175 |
20 |
10 |
18 |
36 |
181 |
29 |
DMSO 100 µL |
17 |
23 |
30 |
174 |
22 |
13 |
20 |
35 |
178 |
28 |
10.0 |
23 |
23 |
37 |
152 |
30 |
21 |
16 |
42 |
166 |
28 |
31.6 |
18 |
17 |
30 |
168 |
25 |
18 |
19 |
42 |
152 |
29 |
100 |
16 |
15 |
36 |
148 |
27 |
13 |
21 |
39 |
142 |
34 |
316 |
25 p |
15 p |
35 p |
163 p |
24 p |
19 p |
18 p |
39 p |
170 p |
32 p |
1000 |
17 p |
23 p |
39 p |
165 p |
26 p |
23 p |
17 p |
36 p |
165 p |
30 p |
p = precipitation
Table 2: Main Assay I, Mean Number of Revertant Colonies per Plate (± SD)
Dose Level (µg/plate) |
Tester Strains Without Metabolic Activation |
Tester Strains With Metabolic Activation |
||||||||
TA 1535 |
TA 1537 |
TA 98 |
TA 100 |
WP2 uvrA |
TA 1535 |
TA 1537 |
TA 98 |
TA 100 |
WP2 uvrA |
|
Untreated |
16 (0.3) |
17 (0.3) |
29 (0.9) |
157 (22.5) |
27 (1.2) |
18 (1.2) |
22 (1.5) |
36 (1.0) |
148 (10.2) |
32 (0.9) |
0.00 |
19 (0.3) |
17 (1.5) |
25 (1.0) |
175 (11.3) |
26 (0.6) |
17 (1.3) |
18 (0.6) |
40 (1.5) |
148 (19.5) |
29 (0.9) |
62.5 |
18 (1.2) |
16 (2.0) |
31 (1.8) |
144 (26.5) |
29 (3.0) |
15 (1.3) |
14 (2.1) |
34 (0.6) |
166 (12.8) |
30 (2.3) |
125 |
18 (1.2) |
14 (0.9) |
29 (0.9) |
156 (16.5) |
31 (2.6) |
19 (0.6) |
14 (1.9) |
35 (1.3) |
167 (17.2) |
29 (0.3) |
250 |
19 (2.0) |
14 (2.0) |
28 (2.1) |
164 (13.0) |
29 (2.3) |
22 (1.2) |
17 (0.9) |
33 (0.9) |
140 (6.6) |
32 (1.5) |
500 |
16 (2.0) p |
18 (1.5) p |
27 (1.9) p |
127 (9.6) p |
33 (2.2) p |
18 (1.5) p |
16 (1.7) p |
31 (2.6) p |
137 (9.5) p |
28 (0.9) p |
1000 |
15 (1.5) p |
14 (2.1) p |
21 (2.6) p |
145 (14.9) p |
23 (0.9) p |
18 (1.5) p |
14 (1.3) p |
29 (1.8) p |
140 (5.2) p |
29 (0.9) p |
p = precipitation
Table 3: Main Assay I, Mean Control Number of Revertant Colonies per Plate (± SD)
Tester Strain |
Without Metabolic Activation |
With Metabolic Activation |
|||||||
Untreated |
SA |
DMSO |
9-AA |
MMS |
2-N |
DMSO |
2-AA |
||
TA 1535 |
Mean (± SD) |
16 (0.3) |
544 (27.9) |
- |
- |
- |
- |
17 (1.3) |
136 (7.8) |
TA 1537 |
Mean (± SD) |
- |
- |
17 (1.5) |
160 (5.5) |
- |
- |
18 (0.6) |
131 (9.5) |
TA 98 |
Mean (± SD) |
- |
- |
25 (1.0) |
- |
- |
177 (6.1) |
40 (1.5) |
555 (27.2) |
TA 100 |
Mean (± SD) |
157 (22.5) |
626 (10.4) |
- |
- |
- |
- |
148 (19.5) |
1021 (41.2) |
WP2uvrA |
Mean (± SD) |
27 (1.2) |
- |
- |
- |
150 (7.1) |
- |
29 (0.9) |
230 (2.9) |
SA = Sodium Azide (1 µg/plate); DMSO = dimethylsulfoxide (100 µL/plate); 2-AA = 2-Aminoanthracene (1 µg/plate or 10 µg/plate for WP2uvrA); 9-AA = 9-Aminoacridine (50 µg/plate); MMS = methylmethanesulfonate (500 µg/plate); 2-N = 2-Nitrofluorene (2 µg/plate).
Table 4: Main Assay II, Mean Number of Revertant Colonies per Plate (± SD)
Dose Level (µg/plate) |
Tester Strains Without Metabolic Activation |
Tester Strains With Metabolic Activation |
||||||||
TA 1535 |
TA 1537 |
TA 98 |
TA 100 |
WP2 uvrA |
TA 1535 |
TA 1537 |
TA 98 |
TA 100 |
WP2 uvrA |
|
Untreated |
19 (0.9) |
17 (0.3) |
29 (1.5) |
162 (13.0) |
27 (1.5) |
18 (1.0) |
20 (0.9) |
41 (0.9) |
153 (13.8) |
32 (1.2) |
0.00 |
15 (2.3) |
17 (1.2) |
28 (1.5) |
145 (10.2) |
24 (3.1) |
20 (0.7) |
18 (0.9) |
41 (1.9) |
162 (6.1) |
34 (0.9) |
31.3 |
14(2.2) |
18 (0.7) |
29 (1.3) |
121 (5.5) |
27 (1.0) |
20 (0.7) |
19 (1.5) |
42 (1.9) |
175 (6.4) |
39 (1.0) |
62.5 |
13 (0.6) |
22 (1.3) |
28 (2.0) |
171 (6.4) |
29 (3.5) |
15 (1.0) |
18 (0.3) |
34 (01.5) |
173 (4.7) |
36 (1.8) |
125 |
15 (1.8) p |
18 (1.2) p |
29 (1.2) p |
154 (8.0) p |
26 (2.0) p |
20 (2.0) p |
20 (3.2) p |
37 (2.4) p |
179 (8.1) p |
40 (0.9) p |
250 |
17 (1.2) p |
15 (1.3) p |
25 (1.8) p |
132 (7.3) p |
28 (2.3) p |
19 (2.3) p |
20 (0.9) p |
38 (2.7) p |
183 (4.2) p |
32 (1.2) p |
500 |
18 (1.8) p |
16 (1.9) p |
29 (1.3) p |
140 (11.6) p |
29 (1.2) p |
23 (0.9) p |
21 (1.2) p |
36 (0.3) p |
172 (2.3) p |
33 (3.5) p |
p = precipitation
Table 5: Main Assay II, Mean Control Number of Revertant Colonies per Plate (± SD)
Tester Strain |
Without Metabolic Activation |
With Metabolic Activation |
|||||||
Untreated |
SA |
DMSO |
9-AA |
MMS |
2-N |
DMSO |
2-AA |
||
TA 1535 |
Mean (± SD) |
16 (2.1) |
465 (16.4) |
- |
- |
- |
- |
20 (1.7) |
114 (6.1) |
TA 1537 |
Mean (± SD) |
- |
- |
20 (1.2) |
153 (18.3) |
- |
- |
25 (1.5) |
122 (2.7) |
TA 98 |
Mean (± SD) |
- |
- |
26 (1.10) |
- |
- |
180 (3.4) |
37 (0.9) |
545 (23.4) |
TA 100 |
Mean (± SD) |
125 (4.7) |
532 (24.2) |
- |
- |
- |
- |
133 (5.1) |
1177 (37.9) |
WP2uvrA |
Mean (± SD) |
25 (1.5) |
- |
- |
- |
192 (4.0) |
- |
33 (1.8) |
235 (17.9) |
SA = Sodium Azide (1 µg/plate); DMSO = dimethylsulfoxide (50 µL/plate); 2-AA = 2-Aminoanthracene (1 µg/plate or 20 µg/plate for WP2uvrA); 9-AA = 9-Aminoacridine (50 µg/plate); MMS = methylmethanesulfonate (500 µg/plate); 2-N = 2-Nitrofluorene (2 µg/plate).
Table 6: Historical Data Without Metabolic Activation
|
Untreated Plate Incorporation |
Untreated Pre-incubation |
Positive Control Plate Incorporation |
Positive Control Pre-incubation |
|
TA 1535 |
Mean |
18 |
18 |
570 |
571 |
SD |
2.6 |
2.4 |
77.2 |
74.6 |
|
n |
164 |
168 |
164 |
168 |
|
TA 1537 |
Mean |
17 |
17 |
169 |
163 |
SD |
2.0 |
1.8 |
34.4 |
42.9 |
|
n |
163 |
168 |
163 |
168 |
|
TA 98 |
Mean |
31 |
32 |
185 |
180 |
SD |
3.2 |
2.9 |
25.0 |
24.4 |
|
n |
166 |
160 |
166 |
160 |
|
TA 100 |
Mean |
143 |
141 |
796 |
804 |
SD |
15.6 |
15.2 |
121.2 |
118.8 |
|
n |
166 |
165 |
166 |
165 |
|
WP2uvrA |
Mean |
28 |
28 |
181 |
212 |
SD |
3.2 |
3.0 |
18.2 |
45.1 |
|
n |
108 |
103 |
108 |
103 |
Table 7: Historical Data With Metabolic Activation
|
Untreated Plate Incorporation |
Untreated Pre-incubation |
Positive Control Plate Incorporation |
Positive Control Pre-incubation |
|
TA 1535 |
Mean |
16 |
16 |
142 |
94 |
SD |
1.7 |
1.8 |
29.0 |
9.9 |
|
n |
164 |
167 |
164 |
167 |
|
TA 1537 |
Mean |
21 |
21 |
121 |
97 |
SD |
2.5 |
2.1 |
20.5 |
11.5 |
|
n |
163 |
169 |
163 |
169 |
|
TA 98 |
Mean |
39 |
40 |
621 |
668 |
SD |
3.8 |
2.9 |
141.3 |
186.1 |
|
n |
166 |
150 |
166 |
150 |
|
TA 100 |
Mean |
152 |
149 |
1282 |
1144 |
SD |
16.1 |
14.6 |
193.8 |
189.6 |
|
n |
167 |
165 |
167 |
165 |
|
WP2uvrA |
Mean |
35 |
34 |
203 |
190 |
SD |
3.4 |
3.1 |
36.6 |
34.5 |
|
n |
107 |
98 |
107 |
98 |
Endpoint conclusion
- Endpoint conclusion:
- no adverse effect observed (negative)
Genetic toxicity in vivo
Endpoint conclusion
- Endpoint conclusion:
- no study available
Additional information
The key studies used in the assessment of the genotoxicity of the registered substance have been assigned a reliability score of 1 using the principles for assessing data quality as set out in Klimisch (1997). These studies,and all the associated supporting studies, which include bacterial reverse mutation, chromosomal aberration and mouse lymphoma assays, indicate that the registered substance does not have a potential to induce genetic toxicity.
The chromosome abberation
Oxidized wax, lithium salt was evaluated for its chromosomal abberation potential in chinese hamster ovary cells accirding to a standardized, OECD 473 Chromosomal abberation study protocol (Wright, 2004) that has been been designated as the key study for this endpoint and given a rating of 1 according to the Klimich criteria. Under the conditions of the test, the test material was determined to be non-clastogenic to human lymphocytes. There was no statistically significant increase in the frequency of cell aberrations in the absence or presence of metabolic activation.
Bactrial reverse mutation (Ames assay)
The key Ames tests of the lithium salt of oxidized wax (Cinelli, 2008) and supporting Ames tests of similar substances have also been included (Cinelli, 2008a and Anonymus 2000a), the results of which were both in agreement with the key studies and were assigned a Klimisch score of 1. In all of these studies the test material was administered to five bacterial strains,S. typhimuriumTA 1535, TA 1537, TA 98, TA 100 andE. coliWP2uvrA, in the presence and absence of metabolic activation using both the plate incorporation and pre-incubation methods. Under the conditions of each test the test material was found to be non-mutagenic in all strains tested.
Mouse lymphoma
A mouse lymphoma study of the lithium salt of oxidized wax (Bisini, 2014) has been provided as key information. Under conditions of the test, the test material did not induce mutation at the TK locus of L5178Y mouse lymphoma cells in vitro in the absence or presence of S9 metabolic activation. This study was performed to OECD and EU guidelines under GLP conditions and was assigned a Klimisch score of 1.
Justification for classification or non-classification
None of the studies conducted on oxidized wax lithium salt included in this evaluation produced results that met the criteria for classification for genotoxicity.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.